NCT05580042View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

PHASE1CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2023

Conditions

Granuloma Annulare

Interventions

DRUG

AC-1101

For each patient, once daily (QD)

Trial Locations (1)

06519

Yale Center for Clinical Investigation, New Haven

All Listed Sponsors

lead

TWi Biotechnology, Inc.

INDUSTRY